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ABSTRACT
Introduction: Geographic transferability of model-based cost–
effectiveness results may facilitate and shorten the reimbursement process
of new pharmaceuticals. This study provides a real world example of
transferring a cost–effectiveness study of trastuzumab for the adjuvant
treatment of HER2-positive early breast cancer from the United Kingdom
to The Netherlands.
Methods: Three successive steps were taken. Step 1: Collect available
information with regard to the original model, and assess transfer-
ability using existing checklists. Step 2: Adapt transferability-
limiting factors. Step 3: Obtain a country-speciﬁc estimate of
cost–effectiveness.
Results: The structure of the UK model was transferable, although some
of the model inputs needed adaptation. From a health-care perspective, the
Dutch estimate amounted to €5828/quality-adjusted life-year gained.
From a societal perspective, the incremental cost–effectiveness ratio was
dominant.
Conclusion: Transferability of a model-based UK-study in three steps
proved to be an efﬁcient method to provide an early indication of the
cost–effectiveness of trastuzumab and has led to the provisional reim-
bursement of the treatment.
Keywords: HER2-positive breast cancer, model-based economic evalua-
tion, transferability, trastuzumab.
Introduction
Geographic transferability of model-based cost–effectiveness
results from other countries can have the potential to facilitate
and shorten the appraisal process regarding the reimbursement
of new pharmaceuticals. Several authors have addressed the
importance of the generalizability of the results of economic
evaluations in health care [1,2]. In addition, checklists have been
developed to assess the degree of transferability of the results of
economic evaluations in health care from one geographic region
to another [3–5].
Still, the actual transferability of in particular model-based
cost–effectiveness results has gained less attention. This study
provides a real world example of transferring a model-based
economic evaluation of trastuzumab (Herceptin; Roche
Netherlands, BV, Woerden, The Netherlands) for the adjuvant
treatment of HER2-positive early breast cancer from the United
Kingdom (UK) to the Dutch setting. Three successive steps were
performed:
1. Checklists were applied to assess transferability of the UK
model.
2. Adaptations to the identiﬁed transferability-limiting factors
were made.
3. Cost–effectiveness of trastuzumab in the Dutch setting was
estimated.
Methods
Step 1: Assess Transferability
The transferability decision chart by Welte et al. consists of
general and speciﬁc knock out criteria of transferability. If the
general knock out criteria are fulﬁlled (i.e., the intervention is not
comparable with the one that shall be used in the decision
country, or the quality of the study is not acceptable) transfer of
the study would be so difﬁcult that conducting a new study is the
better option. Speciﬁc transferability criteria have been devel-
oped to identify study parts that need adaptation. The checklist
by Boulenger et al. consists of 42 questions related to the meth-
odological approach used in the published studies. Each question
can be answered with 1 for “yes,” 0.5 for “partially,” and 0 for
“no,” or “no information.” Because no standard is available to
determine what a certain score means in terms of the level of
transferability, ultimately, a transferability summary score can be
calculated although interpretation is difﬁcult. The checklist by
Urdahl et al. addresses in particular four questions related to: 1)
deﬁnition of target decision-maker or jurisdiction; 2) transparent
reporting of model speciﬁcation; 3) relevance of data inputs to
target decision-maker or jurisdiction; and 4) assessment of
robustness of the model to geographic variation in data inputs.
Step 2: Adapt Factors That Limit Transferability
In Table 1, a detailed overview of speciﬁc transferability criteria
based on the checklist by Welte et al. [3] is given. Transferability
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of the study may be limited because of factors present in each of
these parts. In step 2, transferability-limiting factors were linked
to a speciﬁc study part and it was examined whether it was
feasible to adapt this factor based on existing knowledge.
Step 3: Estimate Country Speciﬁc Cost–Effectiveness
Based on the adapted study parts, a country-speciﬁc estimate of
cost–effectiveness was calculated. Also, uncertainty was
addressed in probabilistic sensitivity analysis and one-way or
n-way sensitivity analyses.
The Case: Model-Based Cost–Effectiveness Analysis of
Trastuzumab in the Early Setting from the UK
In the UK study, a Markov cohort model was used to calculate
the long-term costs, effects, and cost–effectiveness of adjuvant
trastuzumab for 1 year compared with observations (no adjuvant
treatment with trastuzumab in the early breast cancer setting,
although trastuzumab is given to patients who progress to meta-
static disease). The study population consisted of patients aged
50 years and older with HER2-positive early breast cancer. In
Figure 1, all model transitions between the health states are
presented.
Outcomes considered in the model are life-years, quality
adjusted life-years (QALYs), and health-care costs. Cycle length
in the model was 1 year, and the time horizon was 45 years. For
utility and cost calculations, a half-cycle correction was applied.
A probabilistic sensitivity analysis was performed. All model
inputs are presented in Table 2.
Results
Step 1: Transferability Check
Information regarding the UK study included a poster [6], a
technology appraisal by the National Institute for Health and
Clinical Excellence (NICE) [7], a mathematical model, technical
documentation, clinical data, and a costing study (provided by
Roche). The main reason for using the UK model was that its
validity had been established by NICE. In addition, the UK study
passed the general knock out criteria fromWelte et al. [3]. Hence,
the model structure was considered of good quality. As presented
in Table 3, the following input parameters needed adaptation:
price level, discount rate, background mortality, utilities, resource
use, unit prices, and productivity loss. Three questions in the
checklist by Boulenger et al. [4] were answered with “no.” First,
no conversion rate was given; second, no analyses were conducted
to explore geographic variability; and third, caveats regarding the
Table 1 Transferability of the trastuzumab UK model-based cost–effectiveness analysis to The Netherlands according to the Welte checklist
Transferability factor
Direct
inﬂuence on
Estimated relevance
for transferability
UK—Dutch setting
Estimated correspondence
between study and
decision country
Estimation of CER of
decision country based
on CER of study country
Methodological characteristics
Perspective Costs and effects High High Unbiased
Discount rate Costs and effects High Medium Unbiased
Medical cost approach Direct medical costs High Low* Biased
Productivity cost approach Productivity costs Not calculated† — —
Health-care system characteristics
Absolute and relative prices in healthcare Direct medical costs High Low‡ Uncertain
Practice variation Costs and effects High High Unbiased
Technology availability Costs High High Unbiased
Population characteristics
Disease incidence Costs and effects High High Unbiased
Case—mix Costs and effects High High Unbiased
Life expectancy Costs and effects High High Unbiased
Health—status preferences Effects High Low Biased
Acceptance, compliance, incentives to patients Costs and effects — n.a. —
Productivity and work loss time Productivity costs Not calculated† — —
Disease spread Costs and effects Not relevant —
*Detailed cost information per unit was given in the UK cost–effectiveness model.The estimated correspondence was assumed to be low, which led to the decision to replace all resource
valuation with Dutch unit prices; †In the UK cost–effectiveness model, no loss of productivity costs was calculated. In the Dutch setting, the standard approach is the friction cost method;
‡Although detailed cost-information per unit was given in the UK cost–effectiveness model, it was not feasible to assess the difference in absolute and relative prices.Therefore, the decision
was made to use UK resource use but replace UK unit costs by Dutch unit costs.
CER, cost-effectiveness ratio.
Disease Free 
Survival*
Local
Recurrence*
Metastasis*
Death
Death Death
Figure 1 Model transitions between health states (Wardley 2006) [6]. All
patients start in the disease-free survival state and in subsequent cycles they
may move to the other health states: loco-regional/contralateral recurrence,
metastatic disease, and death.The model distinguishes between “severe cardiac
adverse events,” and “other than severe cardiac adverse events” that can occur
during treatment with trastuzumab. Patients who develop a cardiac side effect
during the treatment period are assumed to stop treatment, and from that
moment on have the same risk of developing breast cancer recurrence and
metastasis as nontreated patients. After the occurrence of one of the cardiac
side effects, patients may continue to experience “chronic cardiac adverse
events” for the rest of their lives. *With or without cardiac event.
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generalizability of the results were not discussed. We interpreted
the resulting score of 94%as an adequate description of themodel
inputs. The transferability questions, as formulated by Urdahl
et al., could also be answered. It is common procedure in the UK
that cost–effectiveness analyses are commissioned by NICE. The
manufacturer (i.e., Roche) provides the evidence for submission.
Transition probabilities and health utilities were adequately
described in the technical documentation. The UK resource use
was based on expert opinion (N = 7) and the clinical data input
were derived from the Herceptin Adjuvant (HERA)-trial [14]. An
assessment of the robustness of the model to geographic variation
in data inputs was not included in the UK analysis.
The overall conclusion of the transferability check was that
the structure of the model was transferable to the Dutch setting.
Table 2 Summary of model inputs
United Kingdom The Netherlands
Discount rates Rate (%) Rate (%)
Costs 3.5 4.0
Effects 3.5 1.5
Mean* (€) Lower (€) Upper (€) Mean (€) Lower (€) Upper (€)
Health state costs
One year in disease-free state 2.439 255 5.088 1.276 133 2.663
First year in local- or contralateral recurrence state 18.948 441 34.678 9.370 955 43.238
Cost of a recurrence event 4.591 3.825 5.247 1.605 1.391 1.901
First year in metastatic state 31.375 16.869 53.946 20.192 3.918 52.889
One year in the metastatic state after ﬁrst year 17.538 8.211 27.087 11.266 2.825 22.768
Cardiac-related costs
Severe cardiac adverse events 10.142 7.491 12.792 14.226 7.113 28.452
Other cardiac adverse events 1.952 1.757 2.146 7.113 3.557 14.226
Chronic cardiac adverse events 442 399 487 7.113 3.557 14.226
Heart monitoring per year 1.614 808 2.422 1.275 705 1.394
Trastuzumab-related costs
HER2 test 71 52 88 114 109 420
Trastuzumab in the adjuvant setting 34.188 22.988 45.976 41.541 37.457 49.942
Administration in the adjuvant setting 3.982 3.584 4.379 3.906 3.472 4.340
Trastuzumab in the metastatic setting 24.525 16.491 32.983 29.826 24.000 3.600
Administration in the metastatic setting 7.963 7.167 8.760 9.114 8.680 9.548
Productivity costs Mean
Days lost in recurrence and metastatic state 65 days ﬁxed
Costs per day lost €308 ﬁxed
Utilities for health states Mean Lower Upper Mean Lower Upper
Disease-free survival ﬁrst year 0.749† 0.703 0.795 0.696†† 0.634 0.747
Disease-free survival after ﬁrst year 0.847† 0.807 0.886 0.779†† 0.745 0.811
Metastasis disease ﬁrst year 0.484‡ 0.426 0.542 0.685†† 0.620 0.735
Metastasis disease after ﬁrst year 0.484§ 0.426 0.542 0.685†† 0.620 0.735
Local recurrence 0.810† 0.760 0.870 0.779†† 0.700 0.849
Disutility for events
Local recurrence event 0.240¶ 0.192 0.288 as in UK
Contralateral breast cancer 0.240¶ 0.192 0.288
Cardiac event 0.300** 0.250 0.350
Probabilities‡‡
DFS to contralateral breast cancer§§ 0.007 0.002 0.009 as in UK
DFS to metastasis§§ 0.079 0.039 0.106
DFS to local recurrence§§ 0.029 0.009 0.035
Local recurrence to metastasis 0.078 0.039 0.106
Cardiac adverse events 0.005 0.003 0.010
Cardiac event to local recurrence 0.029 0.009 0.035
Cardiac event to metastasis 0.078 0.039 0.106
Probability of mild cardiac event 0.035 0.030 0.040
Metastasis state to death 0.295 0.200 0.700
HER2 positive rate 20% ﬁxed
Incidence cardiac adverse events 1.2% ﬁxed
Relative risks trastuzumab¶¶ Years
Disease-free survival to local recurrence 1–5 0.510 0.320 1.000 as in UK
5–10 0.663 0.320 1.000
11 to end 0.862 0.320 1.000
Disease-free survival to metastasis 1–5 0.520 0.400 1.000
5–10 0.676 0.400 1.000
11 to end 0.879 0.400 1.000
Local recurrence to metastasis 1–5 0.400 0.150 1.080
5–10 0.520 0.150 1.080
11 to end 0.676 0.150 1.080
Metastasis to death*** 0.800 ﬁxed
Background mortality UK life tables Dutch life tables
*Exchange rate: £1 = €1.4; †Tengs and Wallace, 2000 [8]; ‡Hayman, 1998 [10]; §Carter, 1998 [11]; ¶Van Hanswijck de Jonge, 2006 [12]; **Wardley, 2006 [6]; ††Lidgren, 2007 [13]; ‡‡HERA trial
(Piccart–Gebhart, 2005 [14]); §§After 5 years of simulation in both treatment arms these transition probabilities are adjusted for time in the disease-free state using a stepwise function: 6 to10
years: 0.58, 11 years to end: 0.37 (EBCTCG, 2006 [15]); ¶¶Year 1–5 HERA trial (Piccart–Gebhart, 2005), from year six assumptions; ***Trastuzumab in the metastatic stage is only used in the
‘no trastuzumab’ in the adjuvant setting’ treatment arm.
HERA, Herceptin Adjuvant; DFS, disease-free survival; EBCTG, Early Breast Cancer Trialists’ Collaborative Group.
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Step 2: Adaptations Made to the UK Model-Based
Cost–Effectiveness Study
Table 3 presents an overview of the adaptations to
transferability-limiting study parts. For the adaptation of the
health-care resource use, we could only partly apply the Dutch
data.The reason was that in The Netherlands, no detailed infor-
mation was available about the economic consequences of breast
cancer regarding the various health states. Instead, we used the
UK data because these were readily available, and subsequently
assessed their impact on the incremental cost–effectiveness ratio
(ICER) in sensitivity analyses. More information about the adap-
tations can be found in the appendix at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i4_Essers.asp.
Step 3: Cost–Effectiveness Estimate for the
Dutch Situation
Results (Table 4) indicate that, from a health-care perspective,
treatment with trastuzumab leads to a gain of 2.25 QALYs
(discounted). In terms of cost–effectiveness, the use of trastu-
zumab for a 50 years old patient amounts to €5.828 per QALY
gained (discounted). From a societal perspective (including indi-
rect costs), the ICER is dominant. The acceptability curves
(Fig. 2) show that for the base case analysis (50 years, health-care
perspective), the probability that the net beneﬁt is positive, is 1
for thresholds of €26,000/QALY and higher. One-way sensitivity
analyses demonstrated that results were only sensitive to the use
of trastuzumab in the metastatic phase for the comparator group
(Fig. 3) and not, for example, to a 50% decrease in the costs of
the metastatic phase.
In addition, replacing UK background mortality with Dutch
ﬁgures had virtually no inﬂuence. Using discount rates as recom-
mended in the Netherlands slightly increased the probability of a
positive net beneﬁt although mainly adaptations in the health-
care costs reduced the probability that net beneﬁt was positive
compared with the UK estimate.
As shown in Figure 2, based on cost–effectiveness thresholds
of €14,000 (Dutch societal perspective) and €30,000 (Dutch
health-care perspective), the probability of a positive net beneﬁt
is very close to 1. As a result, for cost–effectiveness thresholds of
€30,000 and higher, the expected value of information is zero.
Because both cost–effectiveness thresholds are considerably
lower than the informal Dutch threshold of €80,000 [9], it is not
meaningful to perform expected value of perfect information
calculations.
Conclusions
In this study, we obtained a Dutch estimate of the cost–
effectiveness of trastuzumab for the early-stage breast cancer
setting based on a model-based cost–effectiveness study devel-
oped for the UK setting, initiated by Roche.
The structure of the UK model was transferable, although
some of the model inputs needed adaptation. Because of the
absence of Dutch data, it was not feasible to fully adapt utilities
and health-care resource use. While the epidemiology of cancer is
very well documented in The Netherlands, there is little informa-
tion about the economic consequences of breast cancer. As a
result, it turned out to be difﬁcult to collect Dutch resource use
on a detailed level. We assumed a high correspondence in practice
Table 3 Overview of the results of step 1 (transferability check) and step 2 (adaptations) in the transferability process
Study part
Step 1
Step 2
Explanation
Transferability
limiting factor Adapted
Model structure
Health states No — Transferable
Events No —
Paths/connections No —
General inputs
Population No — Transferable
Price level Yes Yes Price index ﬁgures*
Discount rate costs Yes Yes Phamacoeconomic guidelines†
Discount rates effects Yes Yes Phamacoeconomic guidelines†
Transition probabilities
Transition probabilities No — Transferable
Risk reductions No — Transferable
Background mortality Yes Yes Dutch life tables*
Utilities assigned to health states/events/paths
Health state description ? Partly No Dutch utilities available. Used Swedish study (Lidgren, 2007) and
expert opinion insteadHealth state valuation Yes Partly
Costs assigned to health states/events/paths
Health-care resource use Yes Partly No Dutch data available
Health-care unit prices Yes Yes Dutch standard prices‡,§, Dutch Hospital prices¶, Dutch
Pharmaceutical Compass**
Patient and family resource use No — Not included in the study
Patient and family unit prices No — Not included in the study
Resource use in other sectors No — Not included in the study
Unit prices in other sectors No — Not included in the study
Productivity costs approach Yes Yes Friction cost method‡,††
Productivity loss Yes Yes Expert opinion
Valuation of lost productivity Yes Yes Dutch standard prices‡
Model analysis
Type of model analysis No — Cohort simulation, transferable
Probabilistic sensitivity analysis No — Transferable
One-way, N-way sensitivity analyses Yes Yes Sensitivity analyses on input parameters (HER2 positivity rate)
and adaptations added
*Dutch Central Bureau of Statistics,www.cbs.nl; †Pharmacoeconomic guidelines,Health Care Insurance Board; ‡Oostenbrink,Dutch manual for costing research; §Cost prices of the Health Care
Insurance Board; ¶Cost prices of the Maastricht University Medical Centre; **Dutch Pharmaceutical Compass; ††Koopmanschap et al. [16].
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variation between the UK and The Netherlands regarding the
various health states (disease-free survival, recurrence, and meta-
static phase) for the group of HER2-positive early breast cancer
patients. Therefore, we decided to use resource volume data
regarding the different health states of the UK study as a proxy
for the Dutch resource use, while we replaced nearly all unit costs
with Dutch estimates. A limitation of the current model adapta-
tion is that the extent to which the use of UK resource volume
data has resulted in an upward or downward bias of the Dutch
cost–effectiveness estimate is unknown. Nevertheless, sensitivity
Table 4 Outcomes deterministic cost–effectiveness analysis base case analysis (50 years, 20% HER2 positive)
United Kingdom Dutch estimate based on UK model based analysis
Trastuzumab No treatment Incremental Trastuzumab No treatment Incremental
Cost (€) QALYs Cost (€) QALYs Cost (€) QALYs ICER (€) Cost (€) QALYs Cost (€) QALYs Cost (€) QALYs ICER (€)
Health-care perspective
Discounted 115.264 10.68 108.900 8.78 6.364 1.91 3.336 89.838 12.98 76.697 10.72 13.142 2.25 5.828
Undiscounted 148.306 15.90 139.119 12.49 9.187 3.41 2.694 112.034 15.73 95.893 12.71 16.140 3.02 5.346
Societal perspective
Discounted 123.727 12.98 132.182 10.72 -8.455 2.25 Dominant
Undiscounted 154.295 15.73 165.266 12.71 -10.971 3.02 Dominant
Cost (€) LY Cost (€) LY Cost (€) LYG ICER (€) Cost (€) LY Cost (€) LY Cost LYG ICER (€)
Health-care perspective
Discounted 115.264 13.56637 108.900 11.69 6.364 1.88 2.417 89.838 17.11 76.697 14.32 13.142 2.79 4.718
Undiscounted 148.306 20.19993 139.119 16.65 9.187 3.55 1.846 112.034 20.70 95.893 16.96 16.140 3.74 4.315
Societal perspective
Discounted 123.727 17.11 132.182 14.32 -8.455 2.79 Dominant
Undiscounted 154.295 20.70 165.266 16.96 -10.971 3.74 Dominant
QALY, quality adjusted life-years; ICER, incremental cost–effectiveness ratio; LY, life-year; LYG, life years gained.
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Figure 2 Cost–effectiveness acceptability curves
for the UK and The Netherlands (health-care
and societal perspective). QALY, quality adjusted
life-years.
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Figure 3 Cost–effectiveness acceptability curves
for sensitivity analyses on the data inputs for the
Dutch health-care perspective. QALY, quality
adjusted life-years.
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analysis showed that the ICER was only sensitive to the use of
trastuzumab in the no comparator group and not, for example,
to a 50% decrease in the costs of the metastatic phase.
A challenge for the geographical transferability of model-
based cost–effectiveness results is the level of transparency in
reporting the model study. This requires not only transparent
reporting of the methods and results, but also access to the
underlying mathematical model. At this moment, this is far from
common. A recommendation to editorial boards and researchers
would be to examine possibilities to make the mathematical
model an integral part of a scientiﬁc publication of a model-
based cost–effectiveness analysis. Another challenge regarding
the transferability of economic evaluations is the availability of
health-care resource data. More attention should be given to a
reliable registration of resource consumption related to the dif-
ferent health states of diseases like, for example, breast cancer.
The analyses in this paper indicated that treatment with tras-
tuzumab results in an average gain of 2.79 life-years and 2.25
QALYs. From a health-care perspective, the cost–effectiveness of
trastuzumab for a patient aged 50 amounts to €5828 per QALY
saved. From a societal perspective, the ICER is dominant. The
ﬁndings of this transferability study support the use of tras-
tuzamab as a cost–effective adjuvant treatment for patients with
HER2-positive early stage breast cancer in The Netherlands. As
such, our study provides a real-world example in which three
successive steps were undertaken to transfer a foreign model-
based economic evaluation. This proved to be an efﬁcient method
in order to obtain an early indication of the cost–effectiveness of
adjuvant trastuzumab and has led to the provisional reimburse-
ment of this treatment in The Netherlands. http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i4_Essers.asp
Source of ﬁnancial support: Roche.
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